Valeant Gets Lender Deal to Waive Default, Loosen Debt Terms

Updated on

Valeant Pharmaceuticals International Inc. won the support of its lenders to waive a default and ease some restrictions on its loan pact as the drugmaker seeks to rein in its $32 billion debt load.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.